Germany's drug regulatory body is attackedBMJ 2006; 333 doi: https://doi.org/10.1136/bmj.39042.547674.94 (Published 23 November 2006) Cite this as: BMJ 2006;333:1087
- Annette Tuffs
The independent institute that assesses new drugs in Germany is facing criticisms similar to those aimed at its equivalent body in the United Kingdom, the National Institute for Health and Clinical Excellence.
Last week in Cologne a member of an association for people with diabetes and representatives of the drug industry walked out of a hearing of the Institute for Quality and Economic Efficiency in Health Care in Cologne because they were not allowed to record the hearing, which was on the use of short acting insulin analogues.
The institute has provoked anger among patients' groups and the drug industry by saying that no evidence has been …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial